Diamedica Inc., of Winnipeg, Manitoba, closed the second tranche of a nonbrokered private placement with an investment of $3 million by Hermed Capital Healthcare Fund to secure 15 million common shares priced at 20 cents apiece. Proceeds will be used to advance Diamedica's R&D programs, including an upcoming trial of DM199, a purified form of the kallikrein known as KLK1, and for other corporate purposes.